Ignite Creation Date:
2024-05-06 @ 1:06 PM
Last Modification Date:
2024-10-26 @ 1:09 PM
Study NCT ID:
NCT03936933
Status:
RECRUITING
Last Update Posted:
2024-05-17
First Post:
2019-04-29
Brief Title:
Pharmacodynamic Study Goserelin 36mg Injection Administered Subcutaneously in Premenopausal Patients With Breast Cancer
Sponsor:
Eurofarma Laboratorios SA
Organization:
Eurofarma Laboratorios SA
Study Overview
Official Title:
Two Arm Multicentric Randomized Open Label Parallel Multiple Dose Study Subcutaneous Injection of Goserelin 36 mg Eurofarma vs ZOLADEX 36 mg AstraZeneca Administered Subcutaneously in Premenopausal Patients With Breast Cancer
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A two arm multi centric randomized open label parallel multiple dose pharmacodynamic study in premenopausal patients with advanced breast cancer
Detailed Description:
A phase III two arm multi centric randomized open label parallel multiple dose pharmacodynamic study in premenopausal patients with breast cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None